Drugs / SAR103168
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00981240 | Sep 2009 → Jan 2012 | acute myeloid leukemia | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR103168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00981240 ↗ |
| Action | Inhibit | “novel multi-targeted kinase inhibitor” PMID 24794806 ↗ Feb 2015 |
| Route | Intravenous | “Route of administration: Intravenous infusion” NCT00981240 ↗ |